CureVac released new test data on Wednesday for the potential, previously unapproved COVID-19 vaccine CVnCoV. In non-human primates, the vaccine caused immunogenicity and protection against the SARS-CoV-2 virus even at low doses. There was a pronounced immune response, according to the Tübimger biotech company. The preclinical data are intended to support the ongoing international clinical phase 2b / 3 efficacy study with the COVID-19 vaccine candidate CVnCoV.
“These data support the protective function of our COVID-19 vaccine candidate CVnCoV and complement our recently published preclinical results,” says Mariola Fotin-Mleczek, Chief Technology Officer of CureVac. “The complete protection of the lungs of vaccinated animals shows the potential of CVnCoV to protect humans from the devastating effects of the virus. It is very encouraging that CVnCoV works at a low dose. The amount is even lower than the dose we are currently testing with in the pivotal clinical trial, ”says the manager.